Previous close | 0.1500 |
Open | 0.1500 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 2.50 |
Expiry date | 2024-07-19 |
Day's range | 0.1500 - 0.1500 |
Contract range | N/A |
Volume | |
Open interest | N/A |
Personalis Inc (PSNL) reports a robust Q1 with significant revenue growth and strategic developments in biopharma collaborations and product launches.
FREMONT, Calif., May 08, 2024--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today reported financial results for the first quarter of 2024 ended March 31, 2024, and provided recent business highlights.
FREMONT, Calif., April 24, 2024--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for cancer, announced today that it will release its first quarter 2024 financial results on Wednesday, May 8, 2024. In conjunction with the release, Personalis will host a conference call and webcast that day at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time to discuss its financial results and recent highlights.